Max Nisen
Columnist
Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.
More From Employee Benefit News
How sticking with ICHRAs minimizes disruption, part 1
Experts suggest locking in this emerging alternative to traditional health insurance coverage to help stabilize soaring health benefit costs.
Benefits Think Rewriting the PBM playbook: Exposing hidden costs and empowering plan sponsors
Part one of this two-part series looks at the background, transparency solutions and how to understand PBM profitability.
Uptick in subrogation lawsuits raises concerns
Advisers should ensure clients have a realistic payment-integrity solution on the front end and robust claims recovery program on the tail end for capturing overpayments.
Trump’s obesity drug plan for Medicare would cost insurers billions
Only 4.4% of newly-eligible patients would be covered by the projected $900 million in savings, according to new research.
Building Chronic Care into Your Benefits Strategy : How Employers Can Support Chronic Disease Management for Better Health Outcomes
Chronic conditions like diabetes, heart disease, cancer, and autoimmune disorders affect more than 60% of Americans —
